StreetInsider.com News Articles

60 Degrees Pharmaceuticals to report babesiosis trial data in January 2027

Tue, 06 Oct 2026 08:10:24 -0400

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) said it will conclude enrollment in its clinical study of tafenoquine in hospitalized babesiosis patients at 30 subjects, three short of the originally planned 33, and expects to report primary and secondary endpoint results in January 2027.

The company's Data Safety Monitoring Board conducted an interim analysis on Oct. 1, 2026, and recommended completing enrollment at the originally planned 33 patients. The study remains blinded. The company said it decided to stop at 30 subjects given the marginal statistical benefit of adding three more patients and the seasonal nature of babesiosis, which could otherwise delay

60 Degrees Pharmaceuticals to report babesiosis trial data in January 2027

Tue, 06 Oct 2026 08:10:24 -0400

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

Tue, 06 Oct 2026 08:10:00 -0400

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded
As of the same date, the Company had enrolled 30 patients
Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027
No safety signals were identified in the study
Published

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

Tue, 06 Oct 2026 08:10:00 -0400

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded
As of the same date, the Company had enrolled 30 patients
Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027
No safety signals were identified in the study
Published

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

Tue, 06 Oct 2026 08:10:00 -0400

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded
As of the same date, the Company had enrolled 30 patients
Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027
No safety signals were identified in the study
Published

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

Tue, 06 Oct 2026 08:10:00 -0400

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded
As of the same date, the Company had enrolled 30 patients
Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027
No safety signals were identified in the study
Published

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Thu, 01 Oct 2026 08:03:00 -0400

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.
Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it will disclose the outcome of the interim analysis from its clinical study evaluating tafenoquine in patients hospitalized with

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Thu, 01 Oct 2026 08:03:00 -0400

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.
Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Thu, 01 Oct 2026 08:03:00 -0400

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.
Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Thu, 01 Oct 2026 08:03:00 -0400

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.
Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Fri, 14 Aug 2026 15:47:00 -0400

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026.

Financial Highlights for the Quarter Ended June 30, 2026:

Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
Gross profit on product revenues was approximately $57 thousand for the

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Fri, 14 Aug 2026 15:47:00 -0400

Financial Highlights for the Quarter Ended June 30, 2026:

Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
Gross profit on product revenues was approximately $57 thousand for the

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Fri, 14 Aug 2026 15:47:00 -0400

Financial Highlights for the Quarter Ended June 30, 2026:

Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
Gross profit on product revenues was approximately $57 thousand for the

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Fri, 14 Aug 2026 15:47:00 -0400

Financial Highlights for the Quarter Ended June 30, 2026:

Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
Gross profit on product revenues was approximately $57 thousand for the

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Fri, 14 Aug 2026 15:47:00 -0400

Financial Highlights for the Quarter Ended June 30, 2026:

Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
Gross profit on product revenues was approximately $57 thousand for the

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Fri, 14 Aug 2026 15:47:00 -0400

Financial Highlights for the Quarter Ended June 30, 2026:

Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
Gross profit on product revenues was approximately $57 thousand for the

60 Degrees Pharmaceuticals raises $1M in private placement

Thu, 30 Jul 2026 14:23:10 -0400

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) has entered into definitive agreements for a private placement expected to raise approximately $1.0 million in gross proceeds, before placement agent fees and other expenses.

The Washington, D.C.-based pharmaceutical company agreed to issue 574,713 shares of common stock, or pre-funded warrants in lieu thereof, along with series A warrants and short-term series B warrants, each to purchase up to 574,713 shares of common stock. The purchase price is $1.74 per share or pre-funded warrant.

Both warrant series carry an exercise price of $1.49 per share and are exercisable upon issuance. The series A warrants expire

60 Degrees Pharmaceuticals raises $1M in private placement

Thu, 30 Jul 2026 14:23:10 -0400

Both warrant series carry an exercise price of $1.49 per share and are exercisable upon issuance. The series A warrants expire

60 Degrees Pharmaceuticals raises $1M in private placement

Thu, 30 Jul 2026 14:23:10 -0400

Both warrant series carry an exercise price of $1.49 per share and are exercisable upon issuance. The series A warrants expire

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules